Advertisement

Proangiogenic and Profibrotic Markers in Pulmonary Sarcoidosis

  • I. TuletaEmail author
  • L. Biener
  • C. Pizarro
  • G. Nickenig
  • D. Skowasch
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1114)

Abstract

The aim of our study was to determine the blood levels of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β1, fibroblast growth factor (FGF)-2, and platelet-derived growth factor (PDGF)-AB in different stages of pulmonary sarcoidosis. There were 92 patients in sarcoidosis stages I + II, III, and IV enrolled into the study. All the patients underwent lung diffusing capacity and blood sampling. We found that VEGF levels differed significantly between the stage groups with the peak VEGF concentrations in stage III. TGF-β1 levels were similar in stages I + II and III, and tended to be lower in stage IV. The analysis of the subgroups showed increased VEGF and FGF-2, and reduced TGF-β1 concentration in stages I + II patients with relevantly reduced lung diffusing capacity or increased sarcoidosis activity compared to patients with normal lung diffusing capacity or inactive sarcoidosis. A tendency towards increased VEGF, PDGF-AB and TGF-β1 levels was observed in the analogical subgroup analysis within the stage III. We conclude that proangiogenic VEGF, and profibrotic FGF-2 and PDGF-AB may contribute to the progression of sarcoidosis, whereas TGF-β1, with its dual anti-inflammatory and profibrotic actions, may play a dichotomous protective or deleterious role. Reduced diffusing capacity and active sarcoidosis are associated with an unfavorable constellation of the markers studied, which predicts a progressive disease course.

Keywords

Angiogenesis Fibrosis Granulomatous disorder Inflammation Markers Matrix accumulation Parenchymal disease Pulmonary sarcoidosis Vascular permeability 

Notes

Acknowledgments

We gratefully acknowledge Ms. Sabine Ring for her excellent technical assistance. We would like to thank all patients who participated in the study and the Sarkoidose-Netzwerk for its support.

Conflicts of Interest

The authors declare no conflicts of interest in relation to this article.

References

  1. Baughman RP, Winget DB, Bowen EH, Lower EE (1997) Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 14:154–158PubMedGoogle Scholar
  2. Fireman E, Gilburd D, Marmor S (2009) Angiogenic cytokines in induced sputum of patients with sarcoidosis. Respirology 14:117–123CrossRefPubMedGoogle Scholar
  3. Hauber HP, Gholami D, Meyer A, Pforte A (2003) Increased interleukin-13 expression in patients with sarcoidosis. Thorax 58:519–524CrossRefPubMedPubMedCentralGoogle Scholar
  4. Iannuzzi MC, Fontana JR (2011) Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 305:391–399CrossRefPubMedGoogle Scholar
  5. Jonth AC, Silveira L, Fingerlin TE, Sato H, Luby JC, Welsh KI, Rose CS, Newman LS, du Bois RM, Maier LA, ACCESS Group (2007) TGF-beta 1 variants in chronic beryllium disease and sarcoidosis. J Immunol 179:4255–4262CrossRefPubMedGoogle Scholar
  6. Judson MA (1999) An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 115:1158–1165CrossRefPubMedGoogle Scholar
  7. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM (2001) Predictingsurvival inidiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164:1171–1181CrossRefPubMedGoogle Scholar
  8. Limper AH, Colby TV, Sanders MS, Asakura S, Roche PC, DeRemee RA (1994) Immunohistochemical localization of transforming growth factor-beta 1 in the nonnecrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med 149:197–204CrossRefPubMedGoogle Scholar
  9. Marie JC, Liggitt D, Rudensky AY (2006) Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25:441–454CrossRefPubMedGoogle Scholar
  10. Marshall BG, Wangoo A, Cook HT, Shaw RJ (1996) Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis. Thorax 51:1253–1261CrossRefPubMedPubMedCentralGoogle Scholar
  11. Nardi A, Brillet PY, Letoumelin P, Girard F, Brauner M, Uzunhan Y, Naccache JM, Valeyre D, Nunes H (2011) Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 38:1368–1373CrossRefPubMedGoogle Scholar
  12. Newman LS, Rose CS, Maier LA (1997) Sarcoidosis. N Engl J Med 336:1224–1234CrossRefPubMedGoogle Scholar
  13. Nishioka Y, Azuma M, Kishi M, Aono Y (2013) Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis. J Med Investig 60:175–183CrossRefGoogle Scholar
  14. Noor A, Knox KS (2007) Immunopathogenesiss of sarcoidiosis. Clin Dermatol 25:250–258CrossRefPubMedGoogle Scholar
  15. Patterson KC, Franek BS, Müller-Quernheim J, Sperling AI, Sweiss NJ, Niewold TB (2013) Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. Cytokine 61:906–911CrossRefPubMedPubMedCentralGoogle Scholar
  16. Piotrowski WJ, Kiszałkiewicz J, Górski P, Antczak A, Górski W, Pastuszak-Lewandoska D, Migdalska-Sęk M, Domańska-Senderowska D, Nawrot E, Czarnecka KH, Kurmanowska Z, Brzeziańska-Lasota E (2015) Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients. BMC Immunol 16:58CrossRefPubMedPubMedCentralGoogle Scholar
  17. Rothe JH, Keitzer R, Röttgen R (2010) Intestinale Sarkoidose – außergewöhnliche Manifestation einer granulomatösen Systemerkrankung. Fortschr Röntgenstr 182:74–76 (Article in German)CrossRefGoogle Scholar
  18. Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y (2003) Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 181:259–265CrossRefPubMedGoogle Scholar
  19. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK (2011) Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 183:1524–1530CrossRefPubMedPubMedCentralGoogle Scholar
  20. Tolnay E, Wiethege T, Kuhnen C, Wulf M, Voss B, Müller KM (1997) Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer. J Cancer Res Clin Oncol 123:652–658CrossRefPubMedGoogle Scholar
  21. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166:1321–1332CrossRefPubMedPubMedCentralGoogle Scholar
  22. Yamashita M, Mouri T, Niisato M, Kowada K, Kobayashi H, Chiba R, Satoh T, Sugai T, Sawai T, Takahashi T, Yamauchi K (2013) Heterogeneous characteristics of lymphatic microvasculatures associated with pulmonary sarcoid granulomas. Ann Am Thorac Soc 10:90–97CrossRefPubMedGoogle Scholar
  23. Ziora D, Dworniczak S, Niepsuj G, Neipsuj K, Jarosz W, Sielska-Sytek E, Ciekalska K, Oklek K (2000) Proangiogenic cytokines (bFGF and VEGF) in BALF from two different lung segments examined by high resolution computed tomography (HRCT) in patients with sarcoidosis. Pneumonol Alergol Pol 68:120–130PubMedGoogle Scholar
  24. Ziora D, Jastrzębski D, Adamek M, Czuba Z, Kozielski JJ, Grzanka A, Kasperska-Zajac A (2015) Circulating concentration of markers of angiogenic activity in patients with sarcoidosis and idiopathic pulmonary fibrosis. BMC Pulm Med 15:113CrossRefPubMedPubMedCentralGoogle Scholar
  25. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J (1996) Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 154:713–719CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • I. Tuleta
    • 1
    Email author
  • L. Biener
    • 1
  • C. Pizarro
    • 1
  • G. Nickenig
    • 1
  • D. Skowasch
    • 1
  1. 1.Department of Internal Medicine II – Cardiology, Pulmonology and AngiologyUniversity of BonnBonnGermany

Personalised recommendations